Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
improved quality of life
reduced viral load increased CD4 count |
| gptkbp:availableIn |
combination therapy
various strengths |
| gptkbp:clinicalTrials |
studied for efficacy
studied for safety studied for resistance |
| gptkbp:contains |
emtricitabine
tenofovir disoproxil fumarate efavirenz |
| gptkbp:contraindication |
pregnancy
severe liver disease hepatotoxicity nephrotoxicity lipodystrophy lactic_acidosis |
| gptkbp:dosageForm |
once daily
|
| gptkbp:formulation |
oral tablet
|
| gptkbp:healthcare |
avoid alcohol
important for effectiveness regular follow-up appointments take on an empty stomach do not skip doses report any severe side effects |
| https://www.w3.org/2000/01/rdf-schema#label |
ATRIPLA
|
| gptkbp:interactsWith |
gptkb:St._John's_Wort
rifampin certain anticonvulsants |
| gptkbp:is_monitored_by |
renal function
liver function viral load CD4 count |
| gptkbp:lastProduced |
2006
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:patentExpiration |
2021
|
| gptkbp:requires |
yes
|
| gptkbp:sideEffect |
depression
dizziness nausea rash insomnia |
| gptkbp:storage |
room temperature
away from moisture |
| gptkbp:suitableFor |
gptkb:CDC
WHO |
| gptkbp:type |
efavirenz/emtricitabine/tenofovir
|
| gptkbp:usedFor |
treatment of HIV
|